Thousands of Americans with early-stage Alzheimer’s disease are now receiving anti-amyloid infusions after federal regulators and Medicare cleared the way for broader access to Leqembi, the first drug in its class to earn traditional FDA approval based on confirmed clinical benefit. At the same time, the pipeline of experimental Alzheimer’s therapies has grown by roughly 40 percent since 2017, with more drugs and trials active in 2026 than in the prior year. The convergence of expanded coverage and accelerating research has created a new reality for patients and clinicians, but it has also exposed gaps in how quickly treatment sites, insurers, and registries can keep pace.
Why Medicare’s registry requirement shapes Leqembi and Kisunla adoption differently
The speed at which patients can actually start treatment depends less on FDA labels than on how payers translate those labels into reimbursable care. When the FDA converted Leqembi from accelerated to traditional approval, it satisfied the evidentiary standard that Medicare had set as a precondition for broad coverage. CMS responded by extending national coverage, provided that patients enroll in a registry under a coverage-with-evidence-development framework. That sequence gave infusion centers and neurologists a concrete operational playbook: confirm the diagnosis, order amyloid testing, enroll the patient in the registry, and begin dosing.
Kisunla, the competing anti-amyloid antibody from Eli Lilly, entered the market without the same head start. Because Leqembi’s traditional approval arrived first, hospitals and specialty pharmacies built their workflows, prior-authorization templates, and registry connections around that drug. Clinics that had already invested in ARIA monitoring protocols and infusion scheduling for Leqembi faced lower friction when adding patients, while sites still setting up infrastructure had to weigh whether to prioritize one drug or both. The result is a structural timing advantage for Leqembi that registry-linked Medicare coverage has reinforced rather than neutralized.
For patients, the practical difference is significant. A Medicare beneficiary whose neurologist already participates in the Alzheimer’s coverage-with-evidence-development registry can begin Leqembi without navigating a separate coverage determination. A patient whose provider has not yet joined the registry, or whose insurer has not finalized a Kisunla reimbursement pathway, faces delays that can stretch weeks or months. In a disease defined by progressive cognitive decline, those delays carry real cost. Clinicians also worry that patients who live far from major academic centers may be left behind if smaller practices struggle to manage registry reporting and infusion logistics.
Pipeline growth since 2017 and what the 2026 trial data show
The surge in approved treatments has coincided with a broader expansion of experimental work. A 2026 pipeline analysis drawing on clinicaltrials.gov data found that the number of Alzheimer’s drugs and trials increased compared with 2025, continuing a trend that has produced an approximately 40 percent increase in active drug development since 2017. That growth spans multiple mechanisms beyond amyloid clearance, including tau-targeting agents, neuroinflammation modulators, synaptic-protection compounds, and metabolic approaches aimed at improving neuronal resilience.
The year-over-year gains reflect both scientific momentum and commercial incentive. Leqembi’s approval demonstrated that regulators would accept a cognitive-decline endpoint as proof of clinical benefit, giving sponsors clearer guidance on what a successful Phase 3 trial needs to show. That signal has drawn new investment into mid-stage programs that might otherwise have stalled during the years when amyloid-targeting drugs repeatedly failed late-stage trials. Companies are also designing trials that enroll patients earlier in the disease course, on the assumption that modifying pathology before extensive neuronal loss may yield larger clinical effects.
Experts have noted that the rising trial count offers fresh optimism for a field that spent more than a decade producing negative results. A recent review of the annual pipeline highlighted changes in active studies, completed trials, and terminated programs, framing the trend as a sign that the research community is testing a wider range of biological targets than at any point in recent memory. Investigators are pairing pharmacologic interventions with more sensitive biomarkers and digital cognitive assessments, hoping to detect treatment effects that traditional scales may miss.
Yet trial counts alone do not guarantee new treatments. Many programs remain in early phases, and the historical failure rate for Alzheimer’s candidates remains among the highest in drug development. Several high-profile agents that showed promise in Phase 2 have stumbled in larger studies when confronted with more heterogeneous patient populations. In addition, the modest effect sizes seen with current anti-amyloid therapies raise questions about how regulators and payers will judge the next wave of drugs, particularly those targeting non-amyloid pathways where surrogate biomarkers are less well validated.
Unanswered questions about patient counts, Kisunla uptake, and registry data
Despite the headline numbers, several gaps in the public record make it difficult to assess how many patients are actually receiving treatment and whether outcomes are tracking the clinical-trial results. Neither CMS nor the FDA has released granular data on how many Medicare beneficiaries have enrolled in the Alzheimer’s coverage-with-evidence-development registry or how many infusions have been administered under that framework. Without those figures, it is hard to know whether “thousands” means five thousand or fifty thousand, or whether uptake is concentrated at a handful of academic medical centers or distributed across community neurology practices.
Kisunla’s adoption trajectory is even less transparent. Public reporting on prescribing volume and payer coverage decisions for the drug remains sparse. Eli Lilly has disclosed some commercial metrics in earnings calls, but no federal dataset tracks real-world Kisunla use with the same structure that the registry provides for Leqembi. That asymmetry makes it challenging to compare how often clinicians choose one drug over the other, how many patients discontinue treatment because of side effects or logistical hurdles, and whether there are systematic differences in access by geography, race, or socioeconomic status.
Researchers and patient advocates argue that more detailed reporting would serve several purposes. First, it would allow independent groups to evaluate whether registry-based coverage is reaching the populations most affected by Alzheimer’s, including rural residents and historically underserved communities. Second, it would help health systems benchmark their own performance on timely diagnosis, referral, and treatment initiation. Third, linking utilization data with outcomes could clarify whether the benefits seen in tightly controlled clinical trials translate into everyday practice, where adherence, comorbidities, and imaging capacity differ markedly.
For now, those questions remain open. Clinicians on the front lines describe a patchwork landscape in which some centers have streamlined pathways that move patients from diagnosis to infusion in a matter of weeks, while others are still building basic infrastructure. Families, meanwhile, must navigate not only the emotional weight of an Alzheimer’s diagnosis but also the practical complexities of insurance authorizations, transportation to infusion centers, and repeated MRI scans. As additional disease-modifying therapies reach the market and the pipeline continues to expand, the challenge will be ensuring that regulatory progress and scientific advances are matched by transparent data and operational systems capable of delivering these treatments equitably and efficiently.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
